ATE218579T1 - Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen - Google Patents
Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogenInfo
- Publication number
- ATE218579T1 ATE218579T1 AT97941352T AT97941352T ATE218579T1 AT E218579 T1 ATE218579 T1 AT E218579T1 AT 97941352 T AT97941352 T AT 97941352T AT 97941352 T AT97941352 T AT 97941352T AT E218579 T1 ATE218579 T1 AT E218579T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- treating infections
- analogues
- indolicidin analogues
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- USSYUMHVHQSYNA-PYODXXEMSA-N (2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-N-[(2R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide Chemical class CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-PYODXXEMSA-N 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2475496P | 1996-08-21 | 1996-08-21 | |
| US3494997P | 1997-01-13 | 1997-01-13 | |
| PCT/US1997/014779 WO1998007745A2 (en) | 1996-08-21 | 1997-08-21 | Compositions and methods for treating infections using analogues of indolicidin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE218579T1 true ATE218579T1 (de) | 2002-06-15 |
Family
ID=26698836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97941352T ATE218579T1 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen |
| AT01119148T ATE410441T1 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01119148T ATE410441T1 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6180604B1 (de) |
| EP (1) | EP0925308B1 (de) |
| JP (2) | JP2001500477A (de) |
| AT (2) | ATE218579T1 (de) |
| CA (1) | CA2263799A1 (de) |
| DE (2) | DE69739035D1 (de) |
| ES (2) | ES2178000T3 (de) |
| HK (1) | HK1043475B (de) |
| WO (1) | WO1998007745A2 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20000918A1 (en) * | 1990-03-22 | 2001-05-30 | Sloan Kettering Inst Cancer | GP75 As a Tumor Vaccine for Melanoma |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6180604B1 (en) * | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| AU2605099A (en) * | 1998-02-25 | 1999-09-15 | Micrologix Biotech, Inc. | Indolicidin and cationic peptides conjugated with polymers |
| US6303575B1 (en) | 1998-05-12 | 2001-10-16 | The Regents Of The University Of California | Indolicidin analogs and methods of using same |
| WO1999065506A2 (en) * | 1998-06-12 | 1999-12-23 | Micrologix Biotech Inc. | Cancer therapy with indolicidin or cationic peptides and their polymer conjugates |
| US6444645B1 (en) * | 1998-06-18 | 2002-09-03 | The Regents Of The University Of California | Crosslink-stabilized indolicidin analogs |
| US6288212B1 (en) * | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
| WO2000026344A1 (en) * | 1998-10-30 | 2000-05-11 | Interlink Biotechnologies Llc | Peptides with enhanced stability to protease degradation |
| US6946261B1 (en) | 1998-11-20 | 2005-09-20 | Migenix Inc. | Efficient methods for producing anti-microbial cationic peptides in host cells |
| AU782306B2 (en) * | 1999-03-03 | 2005-07-21 | Board Of Regents, The University Of Texas System | Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
| US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US6429211B1 (en) * | 2000-05-23 | 2002-08-06 | Bayer Corporation | Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora |
| JP2004501166A (ja) * | 2000-06-16 | 2004-01-15 | ハーキュリーズ・インコーポレーテッド | 化学修飾ペプチド、組成物、並びに製造方法および使用 |
| ATE491459T1 (de) | 2000-10-18 | 2011-01-15 | Pharmasset Inc | Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation |
| DK1353647T3 (da) | 2000-12-27 | 2011-06-14 | Gilead Sciences Inc | Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner |
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7115572B2 (en) * | 2001-03-29 | 2006-10-03 | Council Of Scientific And Industrial Research | Indolicidin analogs with anti-microbial activity |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| US8658202B2 (en) | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| JP2004534084A (ja) * | 2001-06-22 | 2004-11-11 | ザ ホスピタル フォー シック チルドレン | 抗菌ペプチド |
| US6835536B2 (en) | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| US6734165B2 (en) * | 2001-08-23 | 2004-05-11 | The Trustees Of Columbia University In The City Of New York | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide |
| WO2003018619A2 (en) * | 2001-08-24 | 2003-03-06 | Micrologix Biotech Inc. | Antimicrobial and anti-inflammatory peptides |
| US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7166571B2 (en) | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US20030219854A1 (en) * | 2002-03-21 | 2003-11-27 | Micrologix Biotech Inc. | Methods for producing modified anti-infective peptides |
| AU2003226820A1 (en) * | 2002-04-17 | 2003-10-27 | Novartis Ag | Method for the identification of inhibitors of the binding of are-containing mrn a and an hur protein |
| DE60335101D1 (de) * | 2002-04-25 | 2011-01-05 | Toagosei Co Ltd | Antimikrobielles polypeptid und nutzung davon |
| US7345018B2 (en) | 2002-04-25 | 2008-03-18 | Reception Aps | Method of treating side effects induced by therapeutic agents |
| US7601688B2 (en) | 2002-06-13 | 2009-10-13 | Biocon Limited | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| SE0202613D0 (sv) * | 2002-09-04 | 2002-09-04 | Innate Pharmaceuticals Ab | Förfarande och prob för identifiering av ämnen som modifierar bakteriers virulens, som sådana identifierade ämnen samt deras användning |
| US7238669B2 (en) * | 2002-09-11 | 2007-07-03 | The Curators Of The University Of Missouri | Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae |
| US20050245582A1 (en) * | 2002-09-12 | 2005-11-03 | The Hartz Mountain Corporation | High concentration topical insecticides containing pyrethroids |
| WO2005014777A2 (en) * | 2002-10-16 | 2005-02-17 | Board Of Regents, The University Of Texas System | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| CA2514466C (en) | 2003-02-19 | 2015-05-26 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections |
| US20040260454A1 (en) * | 2003-06-11 | 2004-12-23 | Basir Otman A. | Vibro-acoustic engine diagnostic system |
| US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| US20050171063A1 (en) * | 2003-10-20 | 2005-08-04 | Pawan Malhotra | Use of phosphono derivatives as anti-malarials |
| ZA200603215B (en) * | 2003-10-22 | 2007-11-28 | Council Scient Ind Res | Use of selected amino acid-zinc complexes as antimalarial |
| US7674771B2 (en) * | 2003-10-29 | 2010-03-09 | Toagosei Co., Ltd | Antimicrobial peptides and utilization of the same |
| WO2005089738A2 (en) * | 2004-03-17 | 2005-09-29 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
| US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| WO2005090385A2 (en) * | 2004-03-18 | 2005-09-29 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
| MX2007000883A (es) | 2004-07-19 | 2007-04-02 | Biocon Ltd | Conjugados de insulina-oligomero, formulaciones y usos de los mismos. |
| JP4507080B2 (ja) * | 2004-07-30 | 2010-07-21 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US7588885B2 (en) * | 2004-08-06 | 2009-09-15 | Chung Yuan Christian University | Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation |
| US20060068020A1 (en) * | 2004-09-24 | 2006-03-30 | Cottrell Ian W | Encapsulated pharmaceutical agents |
| JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US20090030179A1 (en) * | 2005-02-15 | 2009-01-29 | Toagosei Co., Ltd | Antimicrobial peptide and use thereof |
| CA2617133C (en) | 2005-07-28 | 2014-09-30 | Biosynexus Incorporated | Compositions and methods for treating bacteria |
| WO2008150845A1 (en) * | 2007-05-31 | 2008-12-11 | Vanderbilt University | Screening for wnt pathway modulators and pyrvinium for the treatment of cance |
| BRPI0818004B8 (pt) | 2007-10-16 | 2021-05-25 | Biocon Ltd | composição farmacêutica sólida administrável por via oral e o processo da mesma. |
| ES2559840T3 (es) * | 2008-06-04 | 2016-02-16 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| JP2011195451A (ja) * | 2008-06-20 | 2011-10-06 | Fukuoka Univ | ペプチド |
| US8773662B2 (en) * | 2010-07-22 | 2014-07-08 | Vuv Analytics, Inc. | Methods and apparatus for vacuum ultraviolet (VUV) or shorter wavelength circular dichroism spectroscopy |
| ES2826884T3 (es) * | 2010-08-05 | 2021-05-19 | Helperby Therapeutics Ltd | Combinación de un compuesto de pirroloquinolina y un agente antimicrobiano betalactámico, mupirocina o clorhexidina |
| CN102167731B (zh) * | 2011-02-10 | 2013-01-23 | 周逸明 | 一种固相多肽合成奥米加南的制备方法 |
| US9487476B2 (en) | 2011-10-12 | 2016-11-08 | Yale University | Catechol diethers as potent anti-HIV agents |
| CN105722831B (zh) * | 2013-09-12 | 2019-08-06 | 艾丽奥斯生物制药有限公司 | 哒嗪酮化合物及其用途 |
| US20150141415A1 (en) * | 2013-11-20 | 2015-05-21 | Omonike Arike Olaleye | Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases |
| RU2678985C2 (ru) * | 2017-02-06 | 2019-02-05 | Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" | Биоцидный пептид и препарат на его основе |
| CN108721292B (zh) * | 2018-05-04 | 2022-04-01 | 中国疾病预防控制中心病毒病预防控制所 | 扑蛲灵在制备广谱抗冠状病毒药物中的应用 |
| AU2020292274B2 (en) | 2019-06-13 | 2024-05-23 | Hollister Incorporated | Reusable urinary catheter products |
| CA3140908A1 (en) | 2019-06-25 | 2020-12-30 | Hollister Incorporated | Reusable urinary catheter products |
| KR102433665B1 (ko) * | 2021-11-17 | 2022-08-19 | 주식회사 씨위드 | 인돌리시딘 유래 항균 펩타이드 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2128617A (en) | 1982-10-06 | 1984-05-02 | Martti Vaara | Polypeptides for use in antibacterial therapy |
| NZ237202A (en) | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
| US5324716A (en) | 1991-06-14 | 1994-06-28 | Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5547939A (en) | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5593866A (en) | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| DE69430823T2 (de) | 1993-09-22 | 2003-02-20 | Xoma Technology Ltd., Berkeley | Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum |
| WO1995011670A1 (en) * | 1993-10-25 | 1995-05-04 | The Liposome Company, Inc. | Liposomal defensins |
| PT754050E (pt) | 1994-01-14 | 2002-11-29 | Xoma Technology Ltd | Metodos e materiais contra bacterias gram-positivas |
| US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US5877274A (en) * | 1995-06-02 | 1999-03-02 | University Of British Columbia | Antimicrobial cationic peptides |
| DE69637731D1 (de) | 1995-08-23 | 2008-12-11 | Univ British Columbia | Antimikrobielle kationische peptide und methoden zu ihrer identifizierung |
| US5994308A (en) | 1996-02-28 | 1999-11-30 | Board Of Trustees Of Southern Illinois University | Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use |
| US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6551994B1 (en) | 1997-04-10 | 2003-04-22 | Mcgill University | Compounds and methods for inhibiting the interaction between α-catenin and β-catenin |
| AU2605099A (en) | 1998-02-25 | 1999-09-15 | Micrologix Biotech, Inc. | Indolicidin and cationic peptides conjugated with polymers |
-
1997
- 1997-08-20 US US08/915,314 patent/US6180604B1/en not_active Expired - Lifetime
- 1997-08-21 AT AT97941352T patent/ATE218579T1/de active
- 1997-08-21 CA CA002263799A patent/CA2263799A1/en not_active Abandoned
- 1997-08-21 DE DE69739035T patent/DE69739035D1/de not_active Expired - Lifetime
- 1997-08-21 DE DE69713112T patent/DE69713112T2/de not_active Expired - Lifetime
- 1997-08-21 WO PCT/US1997/014779 patent/WO1998007745A2/en not_active Ceased
- 1997-08-21 EP EP97941352A patent/EP0925308B1/de not_active Expired - Lifetime
- 1997-08-21 ES ES97941352T patent/ES2178000T3/es not_active Expired - Lifetime
- 1997-08-21 ES ES01119148T patent/ES2315252T3/es not_active Expired - Lifetime
- 1997-08-21 JP JP10510994A patent/JP2001500477A/ja active Pending
- 1997-08-21 AT AT01119148T patent/ATE410441T1/de not_active IP Right Cessation
-
2000
- 2000-09-22 US US09/667,486 patent/US6538106B1/en not_active Expired - Fee Related
-
2002
- 2002-07-08 HK HK02105059.5A patent/HK1043475B/en not_active IP Right Cessation
-
2003
- 2003-01-24 US US10/351,985 patent/US7390787B2/en not_active Expired - Fee Related
-
2004
- 2004-08-23 JP JP2004242925A patent/JP4073900B2/ja not_active Expired - Fee Related
-
2008
- 2008-03-28 US US12/058,500 patent/US20080242614A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998007745A2 (en) | 1998-02-26 |
| US6180604B1 (en) | 2001-01-30 |
| HK1043475B (en) | 2009-07-03 |
| JP2005225857A (ja) | 2005-08-25 |
| US20040009910A1 (en) | 2004-01-15 |
| ES2178000T3 (es) | 2002-12-16 |
| US6538106B1 (en) | 2003-03-25 |
| US20080242614A1 (en) | 2008-10-02 |
| WO1998007745A3 (en) | 1998-07-09 |
| JP4073900B2 (ja) | 2008-04-09 |
| HK1021824A1 (en) | 2000-07-07 |
| JP2001500477A (ja) | 2001-01-16 |
| DE69713112T2 (de) | 2003-01-30 |
| DE69739035D1 (de) | 2008-11-20 |
| ATE410441T1 (de) | 2008-10-15 |
| DE69713112D1 (de) | 2002-07-11 |
| HK1043475A1 (en) | 2002-09-13 |
| CA2263799A1 (en) | 1998-02-26 |
| EP0925308A2 (de) | 1999-06-30 |
| EP0925308B1 (de) | 2002-06-05 |
| ES2315252T3 (es) | 2009-04-01 |
| US7390787B2 (en) | 2008-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE410441T1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen | |
| ATE333464T1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
| ES2563677T3 (es) | Composiciones de combinaciones de Neisseria | |
| DE69731373D1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| ATE481480T1 (de) | Methoden und zusammensetzungen zur herstellung von polypeptiden | |
| MX9305729A (es) | Formulas de proteinas de liberacion sostenida. | |
| DE69823046D1 (de) | Praktische in vitro sialylierung von rekombinanten glykpproteinen | |
| NZ227788A (en) | Peptide having growth hormone regulatory effects, and compositions | |
| ATE352617T1 (de) | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| DE60023860D1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
| DK0896615T3 (da) | Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator | |
| DE69900756D1 (de) | Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung | |
| DE59712235D1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe | |
| EP1174439A3 (de) | Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen | |
| ATE385805T1 (de) | Neue peptide | |
| ATE390440T1 (de) | Neuroaktive peptide | |
| ATE405577T1 (de) | Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung | |
| DE60234843D1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
| DE59109235D1 (de) | Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung | |
| DE69726602D1 (en) | Hepatitis b inhibitoren | |
| DE69534738D1 (de) | Leukocyten-aktivierender Faktor | |
| EA199801032A1 (ru) | Белки zona pellucida для контрацепции | |
| SE9604439D0 (sv) | New receptor |